The fact that eEF1A1 appears to be essential for the survival of the tumour cell line PC-3, but not for the non-tumourigenic PZHPV-7 cell line, raises the possibility that the targeting of eEF1A1 preferentially affects prostate tumour cells compared with non-tumourigenic cells, which could overcome the problem of significant side effects of available treatments for CRCP [4]. Here, EEF1A1 is linked to prostate neoplasm.